CASP1 and hematocrit: As specific caspase-1 inhibitors have been confirmed to alleviate BBB deterioration since 2010 (Wu et al., 2010), targeting caspase-1 in stroke contributes to a promising end with a better functional outcome (Wu et al., 2010; Lin et al., 2018; Liang et al., 2019, 2020; Li et al., 2020b; Zhang et al., 2020), milder cerebral edema (Wu et al., 2010; Lin et al., 2018; Liang et al., 2019; Li et al., 2020b; Zhang et al., 2020), and lower occurrence of HT (Ismael et al., 2018; Chen et al., 2021a).